The science…or not behind deferrals of blood donors with a history of cancer.
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
13
05
2023
received:
05
03
2023
accepted:
13
05
2023
medline:
14
8
2023
pubmed:
19
7
2023
entrez:
19
7
2023
Statut:
ppublish
Résumé
In the United States (US), each blood center's medical director sets policy for donors with a cancer history. A subgroup of America's Blood Centers' (ABC) Scientific, Medical, and Technical Committee developed a survey to measure the determination of eligibility, policies for deferral and/or lookback when a donor reports a current diagnosis or history of cancer. A 31-question survey was sent to 47 ABC blood centers in North America via email. Survey results were compiled and literature evaluating the risk of cancer transmission by transfusion was reviewed. Responses were received from 37 centers (79%). Donors with a history of carcinoma or sarcoma who had completed treatment were accepted at 73% of centers with no further deferral. Donors with a history of leukemia or lymphoma were permanently deferred at 76% of centers. Donors with a myelodysplastic or myeloproliferative syndrome were deferred permanently at 86% of centers. Handling of donors with high white cell counts varied. Donors with cancer not in active treatment (i.e., prostate cancer) were subject to various deferrals. Center response to post-donation reports of cancer vary widely. Literature review yielded no evidence of transfusion-transmitted cancer. Cancer deferral policies vary widely among blood centers, and are not generally based on evidence, but on some aspect of the precautionary principle. As the donor population ages and so becomes more at risk of cancer, this approach may further reduce the available donor pool.
Sections du résumé
BACKGROUND
In the United States (US), each blood center's medical director sets policy for donors with a cancer history.
STUDY DESIGN AND METHODS
A subgroup of America's Blood Centers' (ABC) Scientific, Medical, and Technical Committee developed a survey to measure the determination of eligibility, policies for deferral and/or lookback when a donor reports a current diagnosis or history of cancer. A 31-question survey was sent to 47 ABC blood centers in North America via email. Survey results were compiled and literature evaluating the risk of cancer transmission by transfusion was reviewed.
RESULTS
Responses were received from 37 centers (79%). Donors with a history of carcinoma or sarcoma who had completed treatment were accepted at 73% of centers with no further deferral. Donors with a history of leukemia or lymphoma were permanently deferred at 76% of centers. Donors with a myelodysplastic or myeloproliferative syndrome were deferred permanently at 86% of centers. Handling of donors with high white cell counts varied. Donors with cancer not in active treatment (i.e., prostate cancer) were subject to various deferrals. Center response to post-donation reports of cancer vary widely. Literature review yielded no evidence of transfusion-transmitted cancer.
CONCLUSION
Cancer deferral policies vary widely among blood centers, and are not generally based on evidence, but on some aspect of the precautionary principle. As the donor population ages and so becomes more at risk of cancer, this approach may further reduce the available donor pool.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1538-1545Informations de copyright
© 2023 AABB.
Références
Implementation of acceptable full-length and abbreviated donor history questionnaires and accompanying materials for use in screening donors of blood and blood components. Maryland, US: FDA Guidance for Industry; 2020.
Schwartz J, Illoh O, Tanhehco Y. Regulatory considerations in transfusion medicine and cellular therapies. In: Cohn CS, Delaney M, Johnson ST, Katz LM, editors. Technical manual. 20th ed. Bethesda, MD: AABB Press; 2020.
Domínguez-Gil B, Moench K, Watson C, Serrano MT, Hibi T, Asencio JM, et al. Prevention and management of donor-transmitted cancer after liver transplantation: guidelines from the ILTS-SETH consensus conference. Transplantation. 2022;106(1):e12-29. https://doi.org/10.1097/TP.0000000000003995
Desai R, Collett D, Watson CJ, Johnson P, Evans T, Neuberger J. Cancer transmission from organ donors-unavoidable but low risk. Transplantation. 2012;94(12):1200-7. https://doi.org/10.1097/TP.0b013e318272df41
Thiersch J. Attempted transmission of acute leukemia from man to man by the sternal marrow route. Cancer Res. 1946;6(12):695-8.
Thiersch J. Attempted transmission of human leukemia in man. J Lab Clin Med. 1945;30(10):866-74.
Freireich EJ, Levin RH, Whang J, Carbone PP, Bronson W, Morse EE. The function and fate of donors transfused leukocytes from donors with chronic myelogenous leukemia in Leukopenic recipients. Ann N Y Acad Sci. 1964;113:1081-9. https://doi.org/10.1111/j.1749-6632.1964.tb40726.x
Schiffer CA, Aisner J, Dutcher JP, Wiernik PH. Sustained post-transfusion granulocyte count increments following transfusion of leukocytes obtained from donors with chronic myelogenous leukemia. Am J Hematol. 1983;15(1):65-74. https://doi.org/10.1002/ajh.2830150108
Yang TO, Cairns BJ, Reeves GK, Green J, Beral V. Cancer risk among 21st century blood transfusion recipients. Ann Oncol. 2017;28(2):393-9. https://doi.org/10.1093/annonc/mdw555
Cerhan JR, de Sanjosé S, Paige BM, Spinelli JJ, Vajdic CM, Monnereau A, et al. Transfusion history and risk of non-Hodgkin lymphoma (NHL): an Interlymph pooled analysis. Blood. 2014;124(21):3039-9. https://doi.org/10.1182/blood.V124.21.3039.3039
Frietsch T, Steinbicker AU, Horn A, Metz M, Dietrich G, Weigand MA, et al. Safety of intraoperative cell salvage in cancer surgery: an updated meta-analysis of the current literature. Transfus Med Hemother. 2022;49(3):143-57. https://doi.org/10.1159/000524538
Sutton TL, Pasko J, Kelly G, Maynard E, Connelly C, Orloff S, et al. Intraoperative autologous transfusion and oncologic outcomes in liver transplantation for hepatocellular carcinoma: a propensity matched analysis. HPB. 2022;24(3):379-85. https://doi.org/10.1016/j.hpb.2021.06.433
Pinto MA, Grezzana-Filho TJM, Chedid AD, Leipnitz I, Prediger JE, Alvares-da-Silva MR, et al. Impact of intraoperative blood salvage and autologous transfusion during liver transplantation for hepatocellular carcinoma. Langenbecks Arch Surg. 2021;406(1):67-74. https://doi.org/10.1007/s00423-020-01997-7
Weller A, Seyfried T, Ahrens N, Baier-Kleinhenz L, Schlitt HJ, Peschel G, et al. Cell salvage during liver transplantation for hepatocellular carcinoma: a retrospective analysis of tumor recurrence following irradiation of the salvaged blood. Transplant Proc. 2021;53(5):1639-44. https://doi.org/10.1016/j.transproceed.2021.03.025
Tan JKH, Menon N, Tan PS, et al. Presence of tumor cells in intra-operative blood salvage autotransfusion samples from hepatocellular carcinoma liver transplantation: analysis using highly sensitive microfluidics technology. HPB. 2021;23(11):1700-7. https://doi.org/10.1016/j.hpb.2021.04.006
Xu J, Kinnear N, Putra LJ. Safety, efficacy and cost of intra-operative cell salvage during open radical prostatectomy. Transl Androl Urol. 2021;10(3):1241-9. https://doi.org/10.21037/tau-20-1265
21 CFR 630.10. General donor eligibility requirements. Maryland, US: FDA; 2022.
Ludwig H, van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, et al. The European cancer Anaemia survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293-306. https://doi.org/10.1016/j.ejca.2004.06.019
Naoum FA. Iron deficiency in cancer patients. Rev Bras Hematol Hemoter. 2016;38(4):325-30. https://doi.org/10.1016/j.bjhh.2016.05.009
Vahidnia F, Hirschler N, Agapova M, Chinn A, Busch MP, Custer B. Cancer incidence and mortality in a cohort of US blood donors: a 20-year study. J Cancer Epidemiol. 2013;2013:1-11. https://doi.org/10.1155/2013/814842
Zhao J, Dahlén T, Brynolf A, Edgren G. Risk of hematological malignancy in blood donors: a nationwide cohort study. Transfusion. 2020;60(11):2591-6. https://doi.org/10.1111/trf.16020
Cross F. Paradoxical perils of the precautionary principle. Washington Lee Law Rev. 1996;53:851-925. Accessed September 15, 2022. https://scholarlycommons.law.wlu.edu/wlulr/vol53/iss3/2
Birkeland SA, Storm HH. Risk for tumor and other disease transmission by transplantation: a population-based study of unrecognized malignancies and other diseases in organ donors. Transplantation. 2002;74(10):1409-13. https://journals.lww.com/transplantjournal/Fulltext/2002/11270/Risk_for_tumor_and_other_disease_transmission_by.12.aspx
Niederwieser D, Gentilini C, Hegenbart U, Lange T, Moosmann P, Pönisch W, et al. Transmission of donor illness by stem cell transplantation: should screening be different in older donors? Bone Marrow Transplant. 2004;34(8):657-65. https://doi.org/10.1038/sj.bmt.1704588
Edgren G, Hjalgrim H, Reilly M, Tran TN, Rostgaard K, Shanwell A, et al. Risk of cancer after blood transfusion from donors with subclinical cancer: a retrospective cohort study. The Lancet. 2007;369(9574):1724-30. https://doi.org/10.1016/S0140-6736(07)60779-X
Gammon R, editor. Standards for blood banks and transfusion services. 33rd ed. Bethesda, MD: AABB Press; 2022.